MBX Biosciences (MBX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.47B and a free-cash-flow yield of -4.4%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 3.0/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Rising · +120.5% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-29.3%
How far the last close sits under the highest price of the past five years.
Market cap
$2.47B
Trailing P/E
—
Price / book
6.0
Price / sales
—
FCF yield
-4.4%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.1
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
MBX earnings
Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.84).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 6, 2026
-$0.78
-$0.59
-32.2%
$0
Q1 2026
May 7, 2026
-$0.51
-$0.58
+12.1%
$0
Q4 2025
Mar 12, 2026
-$0.49
-$0.60
+18.3%
$0
Q3 2025
Nov 6, 2025
-$0.63
-$0.68
+7.3%
$0
MBX analyst price target
Median target $88.00 from 10 analysts, ranging $80.00 – $150.00.
Nama's AI scorecard currently rates MBX Biosciences Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MBX report earnings?
MBX Biosciences's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.84.
What is the MBX price target?
The median analyst price target from 10 analysts is $88.00, with a range of $80.00 – $150.00.
Is MBX Shariah compliant?
Nama's AAOIFI-style screen reads MBX Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.